文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

骨关节炎:机制与治疗进展

Osteoarthritis: Mechanisms and Therapeutic Advances.

作者信息

Liu Wei, Guo Ning-Yi, Wang Jian-Quan, Xu Bing-Bing

机构信息

Department of Sports Medicine Peking University Third Hospital, Institute of Sports Medicine of Peking University Beijing China.

Beijing Key Laboratory of Sports Injuries Beijing China.

出版信息

MedComm (2020). 2025 Aug 1;6(8):e70290. doi: 10.1002/mco2.70290. eCollection 2025 Aug.


DOI:10.1002/mco2.70290
PMID:40757100
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12314552/
Abstract

Osteoarthritis (OA) is a chronic joint disease characterized by a complex pathological mechanism, including chondrocyte dysfunction, synovial inflammation, subchondral bone remodeling, and molecular regulation abnormalities. Key signaling pathways such as nuclear factor-κB, mitoase-activated protein kinase, and transforming growth factor-β are disrupted, leading to cytokine imbalance, oxidative stress, and excessive protease activity, which collectively contribute to cartilage degeneration. This review summarizes the potential causes of OA, focusing on cellular and structural abnormalities in cartilage, synovial tissue, and subchondral bone, as well as dysregulation of signaling pathways, gene regulation, and molecular mechanisms. Given the limitations of current diagnostic methods for OA, biomarkers may offer new hope. Emerging therapeutic strategies for OA include biologics, intelligent drug delivery, and tissue engineering, aiming to modulate the immune microenvironment while promoting cartilage repair. However, these approaches face challenges such as long-term safety and scalability. Future research may require deeper multidisciplinary collaboration and combination therapies to revolutionize the management of OA and improve patient outcomes.

摘要

骨关节炎(OA)是一种慢性关节疾病,其病理机制复杂,包括软骨细胞功能障碍、滑膜炎症、软骨下骨重塑和分子调节异常。核因子-κB、丝裂原活化蛋白激酶和转化生长因子-β等关键信号通路被破坏,导致细胞因子失衡、氧化应激和蛋白酶活性过高,这些共同导致软骨退变。本综述总结了OA的潜在病因,重点关注软骨、滑膜组织和软骨下骨的细胞和结构异常,以及信号通路失调、基因调控和分子机制。鉴于目前OA诊断方法的局限性,生物标志物可能带来新的希望。OA的新兴治疗策略包括生物制剂、智能药物递送和组织工程,旨在调节免疫微环境同时促进软骨修复。然而,这些方法面临长期安全性和可扩展性等挑战。未来的研究可能需要更深入的多学科合作和联合治疗,以彻底改变OA的管理并改善患者预后。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/eefd/12314552/f651dcef32bc/MCO2-6-e70290-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/eefd/12314552/6efefb5dc92d/MCO2-6-e70290-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/eefd/12314552/d925c369de0e/MCO2-6-e70290-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/eefd/12314552/7e988212661b/MCO2-6-e70290-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/eefd/12314552/b616f3e8ac48/MCO2-6-e70290-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/eefd/12314552/a3f8007ab05c/MCO2-6-e70290-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/eefd/12314552/1023f8248564/MCO2-6-e70290-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/eefd/12314552/f651dcef32bc/MCO2-6-e70290-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/eefd/12314552/6efefb5dc92d/MCO2-6-e70290-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/eefd/12314552/d925c369de0e/MCO2-6-e70290-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/eefd/12314552/7e988212661b/MCO2-6-e70290-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/eefd/12314552/b616f3e8ac48/MCO2-6-e70290-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/eefd/12314552/a3f8007ab05c/MCO2-6-e70290-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/eefd/12314552/1023f8248564/MCO2-6-e70290-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/eefd/12314552/f651dcef32bc/MCO2-6-e70290-g006.jpg

相似文献

[1]
Osteoarthritis: Mechanisms and Therapeutic Advances.

MedComm (2020). 2025-8-1

[2]
Osteoarthritis in cats: what we know, and mostly, what we don't know. . . yet.

J Feline Med Surg. 2025-7

[3]
Transformative approaches for effective clinical trials to reduce the disease burden of osteoarthritis.

Semin Arthritis Rheum. 2025-4

[4]
Ultrasound Phenotype-Based Approach to Treatment Choice in Osteoarthritis.

Life (Basel). 2025-7-19

[5]
Gene therapy pipelines for osteoarthritis: current innovations, operational challenges, and future directions.

Connect Tissue Res. 2025-7-4

[6]
In vitro and in vivo delivery of mRNA to joint cells using polymeric nanoparticles.

Acta Biomater. 2025-6-24

[7]
Management of urinary stones by experts in stone disease (ESD 2025).

Arch Ital Urol Androl. 2025-6-30

[8]
Vitamin D Alleviates Osteoarthritis Progression by Targeting Cartilage and Subchondral Bone via Myd88-TAK1-ERK Axis Suppression.

Drug Des Devel Ther. 2025-7-8

[9]
Recent advances in platelet-rich plasma therapy for osteoarthritis: mechanisms and clinical efficacy.

J Mater Chem B. 2025-7-30

[10]
Exploration of bioactive variants of the BMP7-derived p[63-82] peptide for ameliorating the OA-associated chondrocyte phenotype.

Arthritis Res Ther. 2025-7-30

引用本文的文献

[1]
Analysis of potential molecular targets and mechanisms of brominated flame retardants in causing osteoarthritis using network toxicology, machine learning, SHAP analysis, and molecular dynamics simulation.

BMC Pharmacol Toxicol. 2025-8-18

本文引用的文献

[1]
Circulating miR-126-3p is a mechanistic biomarker for knee osteoarthritis.

Nat Commun. 2025-2-27

[2]
Extracecellulr vesicles (EVs) microRNAs (miRNAs) derived from mesenchymal stem cells (MSCs) in osteoarthritis (OA); detailed role in pathogenesis and possible therapeutics.

Heliyon. 2025-1-27

[3]
Bio-3D printing of scaffold-free ADSC-derived cartilage constructs comparable to natural cartilage in vitro.

J Orthop Surg Res. 2025-2-20

[4]
Osteoarthritis.

Nat Rev Dis Primers. 2025-2-13

[5]
Development and Characterization of Magnetic Nanoemulsion-Based Senolytic Peptides for Osteoarthritis Treatment.

Int J Mol Sci. 2025-2-3

[6]
Therapeutic potential of SOX family transcription factors in osteoarthritis.

Ann Med. 2025-12

[7]
Intra-Articular Injection of Human Bone Marrow-Derived Mesenchymal Stem Cells in Knee Osteoarthritis: A Randomized, Double-Blind, Controlled Trial.

Cell Transplant. 2025

[8]
Co-delivery of IL-1Ra and SOX9 via AAV inhibits inflammation and promotes cartilage repair in surgically induced osteoarthritis animal models.

Gene Ther. 2025-1-20

[9]
Safety and efficacy of mesenchymal stromal cells mitochondria transplantation as a cell-free therapy for osteoarthritis.

J Transl Med. 2025-1-7

[10]
The Intra-Articular Delivery of a Low-Dose Adeno-Associated Virus-IL-1 Receptor Antagonist Vector Alleviates the Progress of Arthritis in an Osteoarthritis Rat Model.

Pharmaceutics. 2024-11-25

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索